Figure 1. Vandetanib treatment leads to a dose-dependent reduction of medulloblastoma cell viability.

The cell lines MEB-Med-8A, D283 Med, Daoy and D341 Med were treated with increasing concentrations of vandetanib. The vehicle DMSO served as control. After 48h of drug exposure the cell viability was assessed by means of the MTS assay. Statistically significant differences from DMSO are marked by an asterisk (*p<0.05), the data shown represent four independent experiments.